|
|
 |
|
Viewing report
|
|
|
|
Novartis: Performance - Products - Pipeline - Potential
Espicom Business Intelligence Ltd, March 2011, Pages: 218
Snapshot Novartis - Oncology leads the way in 2010
The oncology division lead sales growth in 2010, and with oncology being a major focus for Novartis this trend is set to continue. Novartis has an extensive oncology pipeline, the largest of its therapeutic areas, with promising compounds such as panobinostat and midostaurin, which could prove to be future growth drivers.
We predict that Diovan and Glivec/Gleevec will continue to demonstrate substantial sales growth within the medium term. In addition, the launch and approval of a selection of products which include Exjade (deferasirox), Xolair (omalizumab), Exforge (valsartan+amlodipine) and Lucentis (ranibizumab), should offset the decline in sales of a number of Novartis' strategic products.
In the longer term, as a research-intensive company which has benefited from the Chiron acquisition, Novartis has a strong pharmaceutical pipeline with a total of 147 projects under development.
Forecast Sales of Major Products (2009-2017)
But what's in the pipeline?
For the full story on Novartis' challenges and opportunities order this important strategic analysis today
This new strategic report provides a detailed analysis of Novartis' competitive position and prospect for the futures. Using primary source information complemented by original 7-year product forecasts and competitive analysis, the report gives a complete and compelling oversight of the company, its products, pipeline and prospects.
Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.
Customers who bought this item also bought
Novartis AG: PharmaVitae Report
Novartis AG: PharmaVitae Profile
Alcon: Pipeline, Products, Performance & Potential
Roche - Pipeline - Products - Performance - Potential
Ono Pharmaceutical: Pipeline, Products, Performance and Potential
Allergan Inc.: PharmaVitae Profile
Dainippon Sumitomo: Pipeline, Products, Performance, Potential
Takeda Pharmaceutical Co., Ltd: PharmaVitae Profile
sanofi-aventis - Pipeline - Products - Performance - Potential
GW Pharmaceuticals plc - Product Pipeline Review - H2 2011
|
|
|
|
